Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AirSculpt Technologies, Inc. is a U.S.-based medical aesthetics company specializing in body contouring procedures. The company operates within the elective cosmetic surgery and aesthetic medicine industry, focusing on minimally invasive fat removal and body sculpting. Its core offering is the proprietary AirSculpt® procedure, which is positioned as a less invasive alternative to traditional liposuction, designed to reduce downtime, scarring, and anesthesia requirements.
The company primarily serves self-pay consumers seeking cosmetic enhancement, with patients generally paying out of pocket rather than through insurance. AirSculpt differentiates itself through a standardized, brand-driven clinic model, proprietary technology, and centralized marketing and patient acquisition. The company traces its origins to 2012, when it was founded as Elite Body Sculpture, later rebranding to AirSculpt as it expanded nationally and refined its proprietary techniques. AirSculpt Technologies, Inc. completed its initial public offering in 2021 and is listed on the Nasdaq under the ticker AIRS.
Business Operations
AirSculpt generates revenue almost entirely through elective cosmetic procedures performed at its owned and operated centers. Its business is organized around a single reportable operating segment focused on body contouring services delivered through a national clinic network. Procedures include fat removal, fat transfer, and body sculpting treatments, all performed using the company’s proprietary AirSculpt® technology and related protocols.
Operations are primarily domestic, with clinics staffed by employed surgeons and medical personnel operating under standardized clinical, marketing, and pricing models. The company controls its procedure techniques, patient intake systems, and centralized advertising strategy. AirSculpt does not rely on franchising and does not operate significant joint ventures; instead, it maintains full ownership of its clinics, which are typically branded as AirSculpt® Centers.
Strategic Position & Investments
AirSculpt’s strategy centers on expanding its clinic footprint, increasing procedure volume at existing locations, and improving operating efficiency through centralized marketing and scheduling. Growth initiatives have historically included opening new centers in high-income metropolitan markets and expanding awareness of the AirSculpt® brand through national advertising.
The company has pursued selective acquisitions to accelerate growth, most notably the acquisition of Elite Body Sculpture assets prior to its rebranding and public listing, which formed the foundation of its current platform. AirSculpt continues to invest in procedure refinement, patient experience, and data-driven marketing capabilities. While the company operates within the broader aesthetic medicine sector, it remains focused on body contouring rather than diversifying into injectables, skincare, or medical devices.
Geographic Footprint
AirSculpt Technologies operates primarily in the United States, with corporate headquarters located in Miami, Florida. Its clinic network spans multiple major metropolitan areas across the Southeast, Northeast, West Coast, Midwest, and Southwest, giving it a national presence in affluent urban markets.
The company does not currently report material international operations or clinics outside the U.S. Its geographic strategy emphasizes dense urban markets with favorable demographics for elective cosmetic procedures, rather than international expansion.
Leadership & Governance
AirSculpt was founded by Aaron Rollins, who played a central role in developing the company’s original clinical model and growth strategy. Leadership emphasizes brand standardization, operational control, and scalable clinic expansion. The company is governed by a board of directors typical of publicly traded healthcare services firms, with oversight of clinical quality, compliance, and capital allocation.
Key executives include:
- Aaron Rollins – Founder and Executive Chairman
- Dennis Dean – Chief Executive Officer
- Cary Baer – Chief Financial Officer
- Todd Lande – Chief Operating Officer
- Dr. Michael Salzhauer – Chief Medical Officer
Management’s stated strategic vision focuses on disciplined growth, consistent patient outcomes, and reinforcing AirSculpt’s position as a differentiated national brand in minimally invasive body contouring.